Abstract
Alterations in plasma leptin have been reported in schizophrenia patients treated with antipsychotics, suggesting the hypothesis that impairments in leptin secretion or signaling might play a role in antipsychotic-induced weight gain. Plasma leptin was measured in 72 schizophrenia patients chronically treated with olanzapine (n=27), risperidone (n=24) or typical antipsychotics (n=21) and 124 healthy adult control subjects. ANCOVA was used to test effects of adiposity (body mass index kg/m2; BMI), subject group (treated patients vs untreated controls), and treatment group (specific medication groups and untreated controls) on plasma leptin concentrations. Additional analyses were performed in a subset of patients and controls individually matched for BMI to further assess group differences in plasma leptin independent of adiposity. BMI strongly predicted plasma leptin concentrations in the overall sample. In addition, a significant three-way interaction between BMI, subject group, and gender was observed. In the individually BMI-matched sample, modestly reduced plasma leptin levels (effect size 0.4 SD) were observed in treated patients in comparison to the BMI-matched healthy controls, with both groups including males and females. However, no differences in plasma leptin levels were observed in the matched sample when separately comparing male patients vs untreated male controls and female patients vs untreated female controls. Plasma leptin in chronically treated patients with schizophrenia is strongly predicted by adiposity, similar to untreated healthy individuals despite adequate power to detect a difference. The results argue against a role for defective leptin secretion or sensitivity in the weight gain induced by antipsychotic medications.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Allison DB, Casey DE (2001). Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry 62 (Suppl 7): 22–31.
Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC et al (1999). Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 156: 1686–1696.
American Psychiatric Association (1994). Diagnostic and Statistical Manual of Mental Disorders, 4th edn American Psychiatric Association: Washington, DC.
Baptista T, Beaulieu S (2002). Are leptin and cytokines involved in body weight gain during treatment with antipsychotic drugs? Can J Psychiatry 47: 742–749.
Baskin DG, Hahn TM, Schwartz MW (1999). Leptin sensitive neurons in the hypothalamus. Horm Metab Res 31: 345–350.
Bromel T, Blum WF, Ziegler A, Schulz E, Bender M, Fleischhaker C et al (1998). Serum leptin levels increase rapidly after initiation of clozapine therapy. Mol Psychiatry 3: 76–80.
Campfield LA, Smith FJ, Guisez Y, Devos R, Burn P (1995). Recombinant mouse OB protein: evidence for a peripheral signal linking adiposity and central neural networks. Science 269: 546–549.
Casey DE, Haupt DW, Newcomer JW, Henderson DC, Sernyak MJ, Davidson M et al (2004). Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia. J Clin Psychiatry 65: 4–18.
Casey DE, Zorn SH (2001). The pharmacology of weight gain with antipsychotics. J Clin Psychiatry 62 (Suppl 7): 4–10.
Davidson MB, Schriger DL, Peters AL, Lorber B (1999). Relationship between fasting plasma glucose and glycosylated hemoglobin: potential for false-positive diagnoses of type 2 diabetes using new diagnostic criteria. JAMA 281: 1203–1210.
de Graaf C, Blom WA, Smeets PA, Stafleu A, Hendriks HF (2004). Biomarkers of satiation and satiety. Am J Clin Nutr 79: 946–961.
Del Rio G (2000). Adrenomedullary function and its regulation in obesity. Int J Obes Relat Metab Disord 24 (Suppl 2): S89–S91.
Eikelis N, Lambert G, Wiesner G, Kaye D, Schlaich M, Morris M et al (2004). Extra-adipocyte leptin release in human obesity and its relation to sympathoadrenal function. Am J Physiol Endocrinol Metab 286: E744–E752.
Fadel J, Bubser M, Deutch AY (2002). Differential activation of orexin neurons by antipsychotic drugs associated with weight gain. J Neurosci 22: 6742–6746.
Ford ES, Giles WH, Dietz WH (2002). Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 287: 356–359.
Fucetola R, Newcomer JW, Craft S, Melson AK (1999). Age- and dose-dependent glucose-induced increases in memory and attention in schizophrenia. Psychiatry Res 88: 1–13.
Gallagher D, Visser M, Sepulveda D, Pierson RN, Harris T, Heymsfield SB (1996). How useful is body mass index for comparison of body fatness across age, sex, and ethnic groups? Am J Epidemiol 143: 228–239.
Hagg S, Soderberg S, Ahren B, Olsson T, Mjorndal T (2001). Leptin concentrations are increased in subjects treated with clozapine or conventional antipsychotics. J Clin Psychiatry 62: 843–848.
Hamilton BS, Paglia D, Kwan AY, Deitel M (1995). Increased obese mRNA expression in omental fat cells from massively obese humans. Nat Med 1: 953–956.
Heisler LK, Cowley MA, Tecott LH, Fan W, Low MJ, Smart JL et al (2002). Activation of central melanocortin pathways by fenfluramine. Science 297: 609–611.
Herran A, Garcia-Unzueta MT, Amado JA, de La Maza MT, Alvarez C, Vazquez-Barquero JL (2001). Effects of long-term treatment with antipsychotics on serum leptin levels. Br J Psychiatry 179: 59–62.
Hube F, Lietz U, Igel M, Jensen PB, Tornqvist H, Joost HG et al (1996). Difference in leptin mRNA levels between omental and subcutaneous abdominal adipose tissue from obese humans. Horm Metab Res 28: 690–693.
Kershaw EE, Flier JS (2004). Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 89: 2548–2556.
Klein S, Coppack SW, Mohamed-Ali V, Landt M (1996). Adipose tissue leptin production and plasma leptin kinetics in humans. Diabetes 45: 984–987.
Klein S, Wadden T, Sugerman HJ (2002). AGA technical review on obesity. Gastroenterology 123: 882–932.
Kraus T, Haack M, Schuld A, Hinze-Selch D, Kuhn M, Uhr M et al (1999). Body weight and leptin plasma levels during treatment with antipsychotic drugs. Am J Psychiatry 156: 312–314.
Kraus T, Haack M, Schuld A, Hinze-Selch D, Pollmacher T (2001). Low leptin levels but normal body mass indices in patients with depression or schizophrenia. Neuroendocrinology 73: 243–247.
Ma Z, Gingerich RL, Santiago JV, Klein S, Smith CH, Landt M (1996). Radioimmunoassay of leptin in human plasma. Clin Chem 42: 942–946.
Margetic S, Gazzola C, Pegg GG, Hill RA (2002). Leptin: a review of its peripheral actions and interactions. Int J Obes Relat Metab Disord 26: 1407–1433.
Melkersson KI, Hulting AL, Brismar KE (2000). Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses. J Clin Psychiatry 61: 742–749.
Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS et al (2003). Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 289: 76–79.
Montague CT, Farooqi IS, Whitehead JP, Soos MA, Rau H, Wareham NJ et al (1997a). Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature 387: 903–908.
Montague CT, O'Rahilly S (2000). The perils of portliness: causes and consequences of visceral adiposity. Diabetes 49: 883–888.
Montague CT, Prins JB, Sanders L, Digby JE, O'Rahilly S (1997b). Depot- and sex-specific differences in human leptin mRNA expression: implications for the control of regional fat distribution. Diabetes 46: 342–347.
Morimoto T, Yamamoto Y, Yamatodani A (2001). Brain histamine and feeding behavior. Behav Brain Res 124: 145–150.
Mortensen PB, Juel K (1993). Mortality and causes of death in first admitted schizophrenic patients. Br J Psychiatry 163: 183–189.
Newcomer JW, Craft S, Fucetola R, Moldin SO, Selke G, Paras L et al (1999). Glucose-induced increase in memory performance in patients with schizophrenia. Schizophr Bull 25: 321–335.
Nurnberger JIJ, Blehar MC, Kaufmann CA, York-Cooler C, Simpson SG, Harkavy-Friedman J et al (1994). Diagnostic interview for genetic studies. Rationale, unique features, and training. NIMH Genetics Initiative. Arch Gen Psychiatry 51: 849–859; discussion 863–864.
Osby U, Correia N, Brandt L, Ekbom A, Sparen P (2000). Mortality and causes of death in schizophrenia in Stockholm county, Sweden. Schizophr Res 45: 21–28.
Overall JE (1974). A brief psychiatric rating scale in psychopharmacology research. In Pichot P (ed). Psychological Measurements in Psychopharmacology, Modern Problems in Pharmacopsychiatry, 7th edn. Karger: Basel. pp 67–78.
Schwartz MW, Woods SC, Porte DJ, Seeley RJ, Baskin DG (2000). Central nervous system control of food intake. Nature 404: 661–671.
Sobhani I, Buyse M, Goiot H, Weber N, Laigneau JP, Henin D et al (2002). Vagal stimulation rapidly increases leptin secretion in human stomach. Gastroenterology 122: 259–263.
Thakore JH, Mann JN, Vlahos I, Martin A, Reznek R (2002). Increased visceral fat distribution in drug-naive and drug-free patients with schizophrenia. Int J Obes Relat Metab Disord 26: 137–141.
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (2003). Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 26 (Suppl 1): S5–S20.
Tracy RP (2001). Is visceral adiposity the ‘enemy within’? Arterioscler Thromb Vasc Biol 21: 881–883.
Unger RH (2003a). Minireview: weapons of lean body mass destruction: the role of ectopic lipids in the metabolic syndrome. Endocrinology 144: 5159–5165.
Unger RH (2003b). The physiology of cellular liporegulation. Annu Rev Physiol 65: 333–347.
Van Harmelen V, Reynisdottir S, Eriksson P, Thorne A, Hoffstedt J, Lonnqvist F et al (1998). Leptin secretion from subcutaneous and visceral adipose tissue in women. Diabetes 47: 913–917.
World Health Organization (1985). Diabetes Mellitus: Report of a WHO Study Group. World Health Organization:Geneva.
Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM (1994). Positional cloning of the mouse obese gene and its human homologue. Nature 372: 425–432.
Zhang ZJ, Yao ZJ, Liu W, Fang Q, Reynolds GP (2004). Effects of antipsychotics on fat deposition and changes in leptin and insulin levels. Magnetic resonance imaging study of previously untreated people with schizophrenia. Br J Psychiatry 184: 58–62.
Acknowledgements
This study was funded by K23 MH067795, MH63985, Washington University General Clinical Research Center USPHS MO1 RR00036, and Washington University Clinical Nutrition Research Unit Center Grant P30 DK56341.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Haupt, D., Luber, A., Maeda, J. et al. Plasma Leptin and Adiposity During Antipsychotic Treatment of Schizophrenia. Neuropsychopharmacol 30, 184–191 (2005). https://doi.org/10.1038/sj.npp.1300563
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.npp.1300563
Keywords
This article is cited by
-
Chronic treatment with olanzapine increases adiposity by changing fuel substrate and causes desensitization of the acute metabolic side effects
Naunyn-Schmiedeberg's Archives of Pharmacology (2014)
-
Olanzapine promotes fat accumulation in male rats by decreasing physical activity, repartitioning energy and increasing adipose tissue lipogenesis while impairing lipolysis
Molecular Psychiatry (2011)
-
Nestin in Human Skin: Exclusive Expression in Intramesenchymal Skin Compartments and Regulation by Leptin
Journal of Investigative Dermatology (2009)
-
Atypische Neuroleptika und metabolisches Syndrom
Wiener Medizinische Wochenschrift (2007)
-
The impact of hyperactivity and leptin on recovery from anorexia nervosa
Journal of Neural Transmission (2007)
